The findings of the two studies were not unexpected, Mustafa said. “Heterogeneity in medical care is well recognized in ...

Barclays analyst Carter Gould assigned a Buy rating to Regeneron (REGN – Research Report) today and set a price target of $1,080.00. The company’s shares closed last Friday at $933.02. According to ...

On top of this, a stock split generally shows a company is confident about the future, with the idea that the stock could ...

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports third-quarter 2024 results. In the last reported ...

Today, the National Comprehensive Cancer Network® (NCCN®) is presenting preliminary data from a study evaluating the usability of the Health Equity Report Card (HERC) tool during the American Public ...

The Flex CT6 exceeds the AAMI TIR 30 standard making it an effective solution for hospitals, clinics, and other healthcare facilities to clean their surgical equipment. It is easy to use, ...

AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Sanofi (SNYNF – Research Report). The company’s ...

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence. Faricimab and aflibercept show efficacy in DME, RVO, and nAMD, but not all ...

The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics ...